NORTHERN TRUST CORP - VISTAGEN THERAPEUTICS INC ownership

VISTAGEN THERAPEUTICS INC's ticker is VTGN and the CUSIP is 92840H202. A total of 26 filers reported holding VISTAGEN THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.0%.

Quarter-by-quarter ownership
NORTHERN TRUST CORP ownership history of VISTAGEN THERAPEUTICS INC
ValueSharesWeighting
Q1 2023$229,613
+27.6%
1,841,318
+5.4%
0.00%
Q4 2022$179,957
-21.1%
1,747,155
+16.4%
0.00%
Q3 2022$228,000
-83.7%
1,500,532
-5.6%
0.00%
Q2 2022$1,398,000
-31.1%
1,589,048
-2.8%
0.00%
Q1 2022$2,028,000
-46.8%
1,635,003
-16.3%
0.00%
-100.0%
Q4 2021$3,811,000
-30.4%
1,954,286
-2.2%
0.00%0.0%
Q3 2021$5,473,000
-16.4%
1,997,432
-3.9%
0.00%0.0%
Q2 2021$6,550,000
+1069.6%
2,079,179
+690.7%
0.00%
Q1 2021$560,000
+199.5%
262,940
+172.6%
0.00%
Q4 2020$187,000
+152.7%
96,470
-8.8%
0.00%
Q3 2020$74,000
+76.2%
105,786
+32.8%
0.00%
Q2 2020$42,000
+20.0%
79,6820.0%0.00%
Q1 2020$35,000
-27.1%
79,682
+14.4%
0.00%
Q4 2019$48,000
-36.0%
69,6420.0%0.00%
Q3 2019$75,000
+47.1%
69,6420.0%0.00%
Q2 2019$51,000
-42.7%
69,6420.0%0.00%
Q1 2019$89,000
-14.4%
69,6420.0%0.00%
Q4 2018$104,000
+173.7%
69,642
+168.6%
0.00%
Q3 2018$38,000
+5.6%
25,9280.0%0.00%
Q2 2018$36,000
+50.0%
25,9280.0%0.00%
Q1 2018$24,000
+100.0%
25,928
+137.5%
0.00%
Q4 2017$12,000
-29.4%
10,9180.0%0.00%
Q3 2017$17,000
-15.0%
10,9180.0%0.00%
Q2 2017$20,000
-4.8%
10,9180.0%0.00%
Q1 2017$21,00010,9180.00%
Other shareholders
VISTAGEN THERAPEUTICS INC shareholders Q2 2020
NameSharesValueWeighting ↓
ACUTA CAPITAL PARTNERS, LLC 11,728,033$32,135,00011.34%
VR Adviser, LLC 16,047,286$43,970,0005.65%
COMMODORE CAPITAL LP 5,123,509$14,038,0003.70%
Ghost Tree Capital, LLC 2,000,000$5,480,0001.60%
EPIQ PARTNERS, LLC 916,100$2,510,0001.16%
SILVERARC CAPITAL MANAGEMENT, LLC 707,733$1,939,0001.10%
SPHERA FUNDS MANAGEMENT LTD. 3,824,938$10,480,0000.88%
HighVista Strategies LLC 438,239$1,201,0000.80%
Nicholas Investment Partners, LP 2,786,354$7,635,0000.56%
NEA Management Company, LLC 16,302,596$44,669,0000.53%
View complete list of VISTAGEN THERAPEUTICS INC shareholders